119 related articles for article (PubMed ID: 2141513)
1. Antiproliferative effects of suramin on androgen responsive tumour cells.
Berns EM; Schuurmans AL; Bolt J; Lamb DJ; Foekens JA; Mulder E
Eur J Cancer; 1990 Apr; 26(4):470-4. PubMed ID: 2141513
[TBL] [Abstract][Full Text] [Related]
2. Androgens inhibit the proliferation of a variant of the human prostate cancer cell line LNCaP.
Joly-Pharaboz MO; Soave MC; Nicolas B; Mebarki F; Renaud M; Foury O; Morel Y; Andre JG
J Steroid Biochem Mol Biol; 1995 Oct; 55(1):67-76. PubMed ID: 7577722
[TBL] [Abstract][Full Text] [Related]
3. [Androgen regulation of secreted growth factors in prostate carcinoma cell and tumor lines].
Kellner U; Wagner B; Otto U; Voigt KD; Dietel M; Knabbe C
Verh Dtsch Ges Pathol; 1993; 77():124-8. PubMed ID: 7511269
[TBL] [Abstract][Full Text] [Related]
4. Regulation of growth of LNCaP human prostate tumor cells by growth factors and steroid hormones.
Schuurmans AL; Bolt J; Veldscholte J; Mulder E
J Steroid Biochem Mol Biol; 1991; 40(1-3):193-7. PubMed ID: 1958520
[TBL] [Abstract][Full Text] [Related]
5. Androgens stimulate both growth rate and epidermal growth factor receptor activity of the human prostate tumor cell LNCaP.
Schuurmans AL; Bolt J; Mulder E
Prostate; 1988; 12(1):55-63. PubMed ID: 3258066
[TBL] [Abstract][Full Text] [Related]
6. Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer.
Thalmann GN; Sikes RA; Chang SM; Johnston DA; von Eschenbach AC; Chung LW
J Natl Cancer Inst; 1996 Jun; 88(12):794-801. PubMed ID: 8637045
[TBL] [Abstract][Full Text] [Related]
7. Suramin interrupts androgen-inducible autocrine loop involving heparin binding growth factor in mouse mammary cancer (Shionogi carcinoma 115) cells.
Kasayama S; Saito H; Kouhara H; Sumitani S; Sato B
J Cell Physiol; 1993 Feb; 154(2):254-61. PubMed ID: 7678839
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of prostatic tumor cell proliferation by suramin: alterations in TGF alpha-mediated autocrine growth regulation and cell cycle distribution.
Kim JH; Sherwood ER; Sutkowski DM; Lee C; Kozlowski JM
J Urol; 1991 Jul; 146(1):171-6. PubMed ID: 2056586
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor-dependent stimulation of amphiregulin expression in androgen-stimulated human prostate cancer cells.
Sehgal I; Bailey J; Hitzemann K; Pittelkow MR; Maihle NJ
Mol Biol Cell; 1994 Mar; 5(3):339-47. PubMed ID: 8049525
[TBL] [Abstract][Full Text] [Related]
10. Effect of suramin on human prostate cancer cells in vitro.
La Rocca RV; Danesi R; Cooper MR; Jamis-Dow CA; Ewing MW; Linehan WM; Myers CE
J Urol; 1991 Feb; 145(2):393-8. PubMed ID: 1824865
[TBL] [Abstract][Full Text] [Related]
11. Androgens and transforming growth factor beta modulate the growth response to epidermal growth factor in human prostatic tumor cells (LNCaP).
Schuurmans AL; Bolt J; Mulder E
Mol Cell Endocrinol; 1988 Nov; 60(1):101-4. PubMed ID: 3265111
[TBL] [Abstract][Full Text] [Related]
12. Variants of the human prostate LNCaP cell line as tools to study discrete components of the androgen-mediated proliferative response.
Soto AM; Lin TM; Sakabe K; Olea N; Damassa DA; Sonnenschein C
Oncol Res; 1995; 7(10-11):545-58. PubMed ID: 8866667
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of proliferation of human cerebral meningioma cells by suramin: effects on cell growth, cell cycle phases, extracellular growth factors, and PDGF-BB autocrine growth loop.
Schrell UM; Gauer S; Kiesewetter F; Bickel A; Hren J; Adams EF; Fahlbusch R
J Neurosurg; 1995 Apr; 82(4):600-7. PubMed ID: 7897522
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype.
Hobisch A; Ramoner R; Fuchs D; Godoy-Tundidor S; Bartsch G; Klocker H; Culig Z
Clin Cancer Res; 2001 Sep; 7(9):2941-8. PubMed ID: 11555613
[TBL] [Abstract][Full Text] [Related]
15. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
[TBL] [Abstract][Full Text] [Related]
16. Effect of retinoic acid on the proliferation and secretory activity of androgen-responsive prostatic carcinoma cells.
Fong CJ; Sutkowski DM; Braun EJ; Bauer KD; Sherwood ER; Lee C; Kozlowski JM
J Urol; 1993 May; 149(5):1190-4. PubMed ID: 7683344
[TBL] [Abstract][Full Text] [Related]
17. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
[TBL] [Abstract][Full Text] [Related]
18. [The effect of suramin on human lung cancer cell line in vitro].
Fujiuchi S; Tsuji T; Ohsaki Y; Kikuchi K
Gan To Kagaku Ryoho; 1994 Apr; 21(5):647-52. PubMed ID: 8154891
[TBL] [Abstract][Full Text] [Related]
19. Rapid androgen actions on calcium signaling in rat sertoli cells and two human prostatic cell lines: similar biphasic responses between 1 picomolar and 100 nanomolar concentrations.
Lyng FM; Jones GR; Rommerts FF
Biol Reprod; 2000 Sep; 63(3):736-47. PubMed ID: 10952915
[TBL] [Abstract][Full Text] [Related]
20. Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest.
Kokontis JM; Hay N; Liao S
Mol Endocrinol; 1998 Jul; 12(7):941-53. PubMed ID: 9658399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
